For condition: Skin Cancer
Non-melanoma skin cancer Study
Study Summary
Who Can Participate?
Adults aged at least 18 years may participate.
Inclusion Criteria
• Should be with one of the following diseases:
– Diagnosed with primary basal cell carcinoma of the skin by histopathological examination
– Diagnosed with cutaneous squamous cell carcinoma (low risk) by histopathological examination. Low-risk: lesions <2 cm
in diameter with clear borders; pathologic features include highly or moderately differentiated tumors, non-high-risk
histologic subtypes; tumors ≤6 mm in thickness and not infiltrating more than the subcutaneous fat layer, no perineural
infiltration; and no vascular or lymph-vascular infiltration.
– Diagnosed with Bowen’s disease (SCC in situ) by histopathological examination
– Diagnosed with AK by clinical and dermoscopy, or by optional histopathological examination
• Have lesions area of no more than 25 cm² for the whole body, in total; If the total lesion area for the whole body is > 25 cm²,
only a lesion area of no more than 25 cm² will be treated with the study drug.
• Not suitable for surgical or radiotherapy treatment at the lesions area, or unwilling to accept surgical treatment or radiotherapy
Participant Information
• Participate and receive an investigational topical study treatment at no cost
• Regular visits with study doctors who specialize in treating non-melanoma skin cancer and precancerous lesions (about 11 or
15 visits)
• Reimbursement for study-related expenses will be provided
How Long Will Participation Last?
• About 20 or 26 weeks
For more information about this trial, please visit ClinicalTrials.gov
